These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28314411)

  • 41. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
    Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
    J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
    Loiarro M; Capolunghi F; Fantò N; Gallo G; Campo S; Arseni B; Carsetti R; Carminati P; De Santis R; Ruggiero V; Sette C
    J Leukoc Biol; 2007 Oct; 82(4):801-10. PubMed ID: 17548806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A kinome-wide siRNA screen identifies multiple roles for protein kinases in hypoxic stress adaptation, including roles for IRAK4 and GAK in protection against apoptosis in VHL-/- renal carcinoma cells, despite activation of the NF-κB pathway.
    Pan J; Zhang J; Hill A; Lapan P; Berasi S; Bates B; Miller C; Haney S
    J Biomol Screen; 2013 Aug; 18(7):782-96. PubMed ID: 23591012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.
    Zheng X; Ji N; Campbell V; Slavin A; Zhu X; Chen D; Rong H; Enerson B; Mayo M; Sharma K; Browne CM; Klaus CR; Li H; Massa G; McDonald AA; Shi Y; Sintchak M; Skouras S; Walther DM; Yuan K; Zhang Y; Kelleher J; Liu G; Luo X; Mainolfi N; Weiss MM
    J Med Chem; 2024 Oct; 67(20):18022-18037. PubMed ID: 39151120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
    Kumar DM; Patil V; Ramachandran B; Nila MV; Dharmalingam K; Somasundaram K
    Proteomics; 2013 Jul; 13(14):2113-24. PubMed ID: 23595970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly.
    Ferrao R; Zhou H; Shan Y; Liu Q; Li Q; Shaw DE; Li X; Wu H
    Mol Cell; 2014 Sep; 55(6):891-903. PubMed ID: 25201411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.
    Wang Z; Sun D; Johnstone S; Cao Z; Gao X; Jaen JC; Liu J; Lively S; Miao S; Sudom A; Tomooka C; Walker NP; Wright M; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5546-50. PubMed ID: 26526214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and application of PI3K assays for novel drug discovery.
    Yanamandra M; Mitra S; Giri A
    Expert Opin Drug Discov; 2015 Feb; 10(2):171-86. PubMed ID: 25547459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
    ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
    Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
    J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IRAK4 inhibition to shut down TLR signaling in autoimmunity and MyD88-dependent lymphomas.
    Küppers R
    J Exp Med; 2015 Dec; 212(13):2184. PubMed ID: 26666751
    [No Abstract]   [Full Text] [Related]  

  • 53. Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production.
    Valaperti A; Nishii M; Liu Y; Naito K; Chan M; Zhang L; Skurk C; Schultheiss HP; Wells GA; Eriksson U; Liu PP
    Circulation; 2013 Oct; 128(14):1542-54. PubMed ID: 24030499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deciphering the intrinsic dynamics of unphosphorylated IRAK4 kinase bound to type I and type II inhibitors.
    Gosu V; Sasidharan S; Saudagar P; Radhakrishnan K; Lee HK; Shin D
    Comput Biol Med; 2023 Jun; 160():106978. PubMed ID: 37172355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction.
    Inami H; Mizutani T; Watanabe J; Hayashida H; Ito T; Terasawa T; Kontani T; Yamagishi H; Usuda H; Aoyama N; Imamura E; Ishikawa T
    Bioorg Med Chem; 2023 May; 87():117302. PubMed ID: 37201454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues.
    Park Y; Korzun T; Moses AS; Singh P; Levasseur PR; Demessie AA; Sharma KS; Morgan T; Raitmayr CJ; Avila U; Sabei FY; Taratula OR; Marks DL; Taratula O
    Small; 2024 Jan; 20(4):e2306270. PubMed ID: 37702136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.
    Hayakawa N; Noguchi M; Takeshita S; Eviryanti A; Seki Y; Nishio H; Yokoyama R; Noguchi M; Shuto M; Shima Y; Kuribayashi K; Kageyama S; Eda H; Suzuki M; Hatta T; Iemura S; Natsume T; Tanabe I; Nakagawa R; Shiozaki M; Sakurai K; Shoji M; Andou A; Yamamoto T
    Bioorg Med Chem; 2014 Jun; 22(11):3021-9. PubMed ID: 24767819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IRAK4 activation: a cautious embrace.
    Hubbard SR
    Mol Cell; 2014 Sep; 55(6):805-806. PubMed ID: 25238194
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
    McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.